The Pilot Study of Foscarnet Cream in the Treatment of Mucocutaneous Herpes Simplex Virus Infections in Immunocompromised Patients Unresponsive to Acyclovir Treatment
Sponsor: Astra USA
Listed as NCT00002144, this PHASE1 trial focuses on HIV Infections and Herpes Simplex and remains completed. Sponsored by Astra USA, it has been updated 6 times since 2026, reflecting limited change activity. This study is part of the global effort to build evidence for infectious disease interventions.
Change History
6 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE1
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE1
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE1
-
Jun 2018 — Jan 2021 [monthly]
Completed PHASE1
▶ Show 1 earlier version
-
Jan 2017 — Jun 2018 [monthly]
Completed PHASE1
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Astra USA
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
- • Chicago, United States
- • Cleveland, United States
- • Los Angeles, United States
- • Miami, United States
- • Milwaukee, United States
- • New York, United States
- • Providence, United States
- • Washington D.C., United States